December 16, 2016, 9 a.m.
Listen to the call:
Vision, Integrity, Expertise
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Latest News Latest News
Tuesday, February 2nd, 2016
Relevant Publications Publications
Wednesday, October 28th, 2015
Partnering with Us
Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of oncology, supportive cancer care, gastrointestinal and biodefense.